Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7086927 | 0.97 | RAB9A (0.47) | RAB9ANPC1MAPTHSD17B1MAPK1 | |
| SCHEMBL5578268 | 0.85 | ALDH1A1 (0.61) | MAPTMAPK1PDE4DHDAC6ALDH1A1 | |
| SCHEMBL7849056 | 0.83 | RAB9A (0.46) | RAB9ANPC1MAPTHSD17B1MAPK1 | |
| SCHEMBL13928814 | 0.83 | NPC1 (0.56) | RAB9ANPC1MAPTHSD17B1HDAC6 | |
| SCHEMBL29793289 | 0.80 | NPC1 (0.67) | RAB9ANPC1MAPTHSD17B1KCNJ1 | |
| SCHEMBL21584068 | 0.80 | NPC1 (0.67) | RAB9ANPC1MAPTHSD17B1KCNJ1 | |
| SCHEMBL3440214 | 0.80 | RAB9A (0.53) | RAB9ANPC1MAPTHSD17B1MAPK1 | |
| SCHEMBL1982216 | 0.79 | RAB9A (0.51) | RAB9ANPC1MAPTHSD17B1MAPK1 | |
| SCHEMBL12039308 | 0.79 | MAOA (0.52) | RAB9ANPC1MAPTHSD17B1MAPK1 | |
| SCHEMBL33121 | 0.77 | ALDH1A1 (0.68) | RAB9ANPC1MAPTHSD17B1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885MAPT 2628/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | RAB9A 1065/4885NPC1 1752/4885MAPT 2628/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | RAB9A 3039/4885NPC1 469/4885MAPT 79/4885 |
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | RAB9A 4170/4885NPC1 1334/4885MAPT 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.